March 24, 2022 -- Akron BioProducts and Vor Bio have announced an agreement to develop and manufacture current good manufacturing practice nucleases.
The collaboration strengthens Akron's portfolio of off-the-shelf gene editing technologies and broadens Vor Bio's collection of nucleases to engineer gene modified cell therapies, the companies said.
The collaboration also will focus on developing and manufacturing starting materials needed to advance potential treatments for blood cancers, the companies said.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
